Lonza Group AG (LZAGF) Research

Lonza Group AG, established in 1897 and based in Basel, Switzerland, is a global enterprise that furnishes critical products and services to the pharmaceutical, biotechnology, and nutrition sectors. Its operational footprint extends across Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and beyond. The company's activities are organized into four primary divisions: Biologics: This segment is dedicated to the contract development and manufacturing (CDMO) of biopharmaceuticals, offering extensive support for both drug substances and finished drug products throughout their entire lifecycle, from clinical trials to commercial-scale production. Small Molecules: Operating as a fully integrated service provider, this division handles the development and manufacturing of small molecule active pharmaceutical ingredients and their intermediate compounds, guiding clients through all stages of design, development, and production. Cell & Gene: This segment focuses on advancing technologies and platforms to industrialize the manufacturing processes of cell and gene therapies. It also provides comprehensive contract development, manufacturing, and regulatory guidance for a diverse range of allogeneic and autologous cell therapies, exosome-based treatments, and viral vector gene therapies. Additionally, it supplies specialized raw materials and enabling technological solutions vital for cell and gene therapy, injectable medications, vaccines, and biomanufacturing markets. Capsules & Health Ingredients: This division delivers various capsules, innovative dosage form solutions, and health-promoting ingredients to pharmaceutical and nutraceutical customers.

Open Lonza Group AG (LZAGF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.